EY Acquires Aqurance to Drive Life Sciences Transformation Powered by Veeva Technology
In a significant move to bolster its position in the life sciences sector, EY has officially announced the acquisition of Aqurance, a prominent Veeva services partner based in Greece. This strategic acquisition will allow EY to amplify its expertise in clinical, regulatory, and commercial services that cater to the global pharmaceutical and biotechnology industries.
As the life sciences sector continues to evolve rapidly, companies are faced with intricate decisions regarding platform migrations, regulatory compliance, and data integration. The €lliance between EY and Aqurance is set to transform these challenges into streamlined opportunities. By integrating Aqurance’s specialized Veeva Vault services with EY’s vast knowledge in regulatory frameworks, business design, and technology integration, clients will benefit from a comprehensive and compliant path forward.
Aqurance has earned its reputation as a Premier Services Partner for Veeva Commercial Cloud and a Services Partner for Veeva Development Cloud, which makes this acquisition a logical step for EY. The combined resources will not only elevate client engagements in commercial and research and development (R&D) areas, but also enhance EY’s overall service offerings in managing technology deployment and operations.
With this acquisition, EY aims to enhance its Veeva Centers of Excellence, further supporting clients as they navigate the complexities of adopting a unified platform that standardizes operations, improves customer engagement, and accelerates clinical trial processes. The partnership is built upon the principle that data and AI can be leveraged to make informed, strategic decisions throughout the value chain.
Dan Mathews, EY’s Global Life Sciences Leader, expressed that this acquisition represents a pivotal moment in the industry. He emphasized that the collaboration will empower life sciences companies to innovate faster while remaining compliant and efficiently managing data. This effort will facilitate a seamless integration of strategies that enhances client outcomes.
Dionissis Nikolopoulos, the Founder and CEO of Aqurance, indicated that choosing EY as their partner was a critical decision. He noted that EY’s global presence and transformative capabilities are crucial for amplifying the impact of Aqurance’s offerings.
Looking ahead, the EY-Aqurance partnership is excited to showcase their joint capabilities at the upcoming Veeva Commercial Summit in Madrid, scheduled for November 5-6, 2025. This event presents an opportunity for potential clients to engage directly with the innovative solutions being developed through this strategic alliance.
In conclusion, EY’s acquisition of Aqurance marks a significant advancement in their commitment to driving digital evolution in the life sciences sector. As market dynamics shift and technology advances, this partnership stands to ensure that clients can transition smoothly through necessary transformations, positioning themselves for future success in an ever-changing landscape.
For additional insights into EY’s offerings in the life sciences space, interested parties can visit the EY website at ey.com/lifesciences.
As the life sciences sector continues to evolve rapidly, companies are faced with intricate decisions regarding platform migrations, regulatory compliance, and data integration. The €lliance between EY and Aqurance is set to transform these challenges into streamlined opportunities. By integrating Aqurance’s specialized Veeva Vault services with EY’s vast knowledge in regulatory frameworks, business design, and technology integration, clients will benefit from a comprehensive and compliant path forward.
Aqurance has earned its reputation as a Premier Services Partner for Veeva Commercial Cloud and a Services Partner for Veeva Development Cloud, which makes this acquisition a logical step for EY. The combined resources will not only elevate client engagements in commercial and research and development (R&D) areas, but also enhance EY’s overall service offerings in managing technology deployment and operations.
With this acquisition, EY aims to enhance its Veeva Centers of Excellence, further supporting clients as they navigate the complexities of adopting a unified platform that standardizes operations, improves customer engagement, and accelerates clinical trial processes. The partnership is built upon the principle that data and AI can be leveraged to make informed, strategic decisions throughout the value chain.
Dan Mathews, EY’s Global Life Sciences Leader, expressed that this acquisition represents a pivotal moment in the industry. He emphasized that the collaboration will empower life sciences companies to innovate faster while remaining compliant and efficiently managing data. This effort will facilitate a seamless integration of strategies that enhances client outcomes.
Dionissis Nikolopoulos, the Founder and CEO of Aqurance, indicated that choosing EY as their partner was a critical decision. He noted that EY’s global presence and transformative capabilities are crucial for amplifying the impact of Aqurance’s offerings.
Looking ahead, the EY-Aqurance partnership is excited to showcase their joint capabilities at the upcoming Veeva Commercial Summit in Madrid, scheduled for November 5-6, 2025. This event presents an opportunity for potential clients to engage directly with the innovative solutions being developed through this strategic alliance.
In conclusion, EY’s acquisition of Aqurance marks a significant advancement in their commitment to driving digital evolution in the life sciences sector. As market dynamics shift and technology advances, this partnership stands to ensure that clients can transition smoothly through necessary transformations, positioning themselves for future success in an ever-changing landscape.
For additional insights into EY’s offerings in the life sciences space, interested parties can visit the EY website at ey.com/lifesciences.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.